Reni J. Benjamin
Stock Analyst at Citizens
(3.03)
# 1,076
Out of 5,090 analysts
13
Total ratings
45.45%
Success rate
4.88%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Reni J. Benjamin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZYME Zymeworks | Initiates: Market Outperform | $32 | $26.69 | +19.90% | 1 | Dec 3, 2025 | |
| ONC BeOne Medicines AG | Maintains: Market Outperform | $348 → $396 | $322.90 | +22.64% | 1 | Nov 7, 2025 | |
| SANA Sana Biotechnology | Maintains: Market Outperform | $5 → $8 | $5.13 | +55.95% | 1 | Oct 30, 2025 | |
| SMMT Summit Therapeutics | Reiterates: Market Outperform | $40 | $18.31 | +118.46% | 3 | Oct 20, 2025 | |
| KURA Kura Oncology | Reiterates: Market Outperform | $24 | $11.95 | +100.84% | 2 | Oct 20, 2025 | |
| INBX Inhibrx Biosciences | Reiterates: Market Perform | n/a | $89.47 | - | 1 | Aug 22, 2025 | |
| HOWL Werewolf Therapeutics | Maintains: Market Outperform | $4 → $3 | $0.95 | +215.23% | 1 | Aug 21, 2025 | |
| PRLD Prelude Therapeutics | Maintains: Market Outperform | $4 → $3 | $1.46 | +105.48% | 1 | Aug 18, 2025 | |
| BCAB BioAtla | Downgrades: Market Perform | n/a | $0.82 | - | 1 | Aug 13, 2025 | |
| BCYC Bicycle Therapeutics | Maintains: Market Outperform | $22 → $10 | $7.07 | +41.44% | 1 | Aug 12, 2025 |
Zymeworks
Dec 3, 2025
Initiates: Market Outperform
Price Target: $32
Current: $26.69
Upside: +19.90%
BeOne Medicines AG
Nov 7, 2025
Maintains: Market Outperform
Price Target: $348 → $396
Current: $322.90
Upside: +22.64%
Sana Biotechnology
Oct 30, 2025
Maintains: Market Outperform
Price Target: $5 → $8
Current: $5.13
Upside: +55.95%
Summit Therapeutics
Oct 20, 2025
Reiterates: Market Outperform
Price Target: $40
Current: $18.31
Upside: +118.46%
Kura Oncology
Oct 20, 2025
Reiterates: Market Outperform
Price Target: $24
Current: $11.95
Upside: +100.84%
Inhibrx Biosciences
Aug 22, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $89.47
Upside: -
Werewolf Therapeutics
Aug 21, 2025
Maintains: Market Outperform
Price Target: $4 → $3
Current: $0.95
Upside: +215.23%
Prelude Therapeutics
Aug 18, 2025
Maintains: Market Outperform
Price Target: $4 → $3
Current: $1.46
Upside: +105.48%
BioAtla
Aug 13, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $0.82
Upside: -
Bicycle Therapeutics
Aug 12, 2025
Maintains: Market Outperform
Price Target: $22 → $10
Current: $7.07
Upside: +41.44%